Development of an <sup>18</sup>F-labeled azobenzothiazole tracer for α-synuclein aggregates in the brain-Reference-Cited by-同舟云学术

Development of an ¹⁸F-labeled azobenzothiazole tracer for α-synuclein aggregates in the brain

Published:2024 Issue:22 Volume:22 Page:4550-4558
ISSN:1477-0520
Container-title:Organic & Biomolecular Chemistry
language:en
Short-container-title:Org. Biomol. Chem.

Author:

Wu Jiajun¹,Mao Meiting¹,Yang Jie¹,Li Kexin¹,Deng Pengxin¹,Zhong Jing¹,Wu Xiaoai²,Cheng Yan¹^ORCID

Affiliation:

1. Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China

2. Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China

Abstract

Compact benzothiazole derivatives were developed as specific probes for aggregated α-synuclein protein. Among them, fluoropegylated azobenzothiazole [18F]NN-F exhibits efficient brain uptake and specific labeling of α-synuclein aggregates.

Funder

Fundamental Research Funds for the Central Universities

Higher Education Discipline Innovation Project

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/OB/D4OB00492B

Reference44 articles.

1. Challenges in the diagnosis of Parkinson's disease

2. Adjunctive Therapies in Parkinson Disease—Have We Made Meaningful Progress?

3. Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update

4. α-Synuclein in Lewy bodies

5. The many faces of α-synuclein: from structure and toxicity to therapeutic target